CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade)
Source: SeekingAlpha
2025-12-24 07:00:30 ET
Overview
My last look at CytomX Therapeutics, Inc. ( CTMX ) was in October and followed preliminary data for its EpCAM-targeted, topo-1 Probody-ADC, CX-2051....
Read the full article on Seeking Alpha
For further details see:
CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade)
CytomX Therapeutics Inc.
NASDAQ: CTMX
CTMX Trading
4.44% G/L:
$4.82 Last:
775,333 Volume:
$4.61 Open:
CTMX Latest News
March 04, 2026 08:00:00 am
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
January 27, 2026 07:00:00 am
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
CTMX Stock Data
$945,449,504
141,817,426
0.97%
31
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
